BioCentury | May 28, 2020
Distillery Therapeutics

Reducing kidney damage in lupus by targeting HIF1A

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Inhibiting HIF1A could treat lupus by reducing hypoxia-mediated kidney damage by T cells. In renal biopsies from systemic lupus erythematosus patients, tissue with high T cell infiltration had higher...
BioCentury | Feb 8, 2019
Product R&D

Reducing R(i)SK in TNBC

Phoenix Molecular Designs could provide triple-negative breast cancer its first molecular marker to turn the intractable indication from a group of have-nots to a group of haves. With early evidence that RSK2 is activated in...
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
BioCentury | Aug 18, 2016
Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase α (PI3Kα); pyruvate dehydrogenase kinase 1 (PDK1); serum/glucocorticoid regulated kinase 1 (SGK1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting PDK1 or SGK1 could help treat PI3Kα inhibitor-resistant breast cancer. In breast cancer patients, high tumor expression of SGK1 correlated with resistance...
BioCentury | Feb 11, 2016
Translation in Brief

Sugar rush

Partikula LLC is developing a series of compounds that elevate glucose and deplete lactate in the tumor microenvironment by modulating metabolism in tumors. Preclinical data for the lead compound - the tumor-targeted pyruvate dehydrogenase kinase (PDK)...
BioCentury | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Pyruvate dehydrogenase kinase 2 (PDK2); PDK4

Neurology INDICATION: Pain Mouse studies suggest dual PDK2 / PDK4 inhibitors could help treat inflammatory pain. In mice, intraplantar administration of an inflammatory adjuvant increased hindpaw expression of PDK2 and PDK4 compared with vehicle. In...
BioCentury | May 22, 2014
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Restenosis Pyruvate dehydrogenase kinase 2 (PDK2) Rodent, rabbit and porcine studies suggest inhibiting PDK2 in coronary artery transplants could prevent restenosis. In rodent and...
BioCentury | Dec 19, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Staurosporine analogs (staralogs) with improved selectivity toward analog-sensitive kinases Staralogs could expand approaches to study kinase function using analog-sensitive kinase variants. Kinase variants with genetically...
BioCentury | Jun 13, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Pyruvate dehydrogenase kinase 1 (PDK1) Cell culture and mouse studies suggest inhibiting PDK1 could help treat melanoma. In a mouse...
Items per page:
1 - 10 of 17